Previous 10 | Next 10 |
Accomplished Former COO of Deloitte Brings Extensive Strategic, Operational and Business Expertise Deciphera Pharmaceuticals, Inc . (Nasdaq:DCPH), a clinical-stage biopharmaceutical company addressing key mechanisms of tumor drug resistance, today announced that it has elected Frank ...
Healthcare Pulse Healthcare is at its all-time highs eclipsing the highs recorded a year earlier during the Oct-Nov 2018 period. Of course, if one looks at the broader market which has been recording such all-time highs since the summer of this year, it's understandable to shrug shoulders ...
- Preliminary Anti-tumor Activity Observed in Initial Diffuse-type TGCT Patients Treated with DCC-3014 in Ongoing Phase 1 Study - - DCC-3014 was Generally Well Tolerated with No Reported Grade 3 or Higher TEAEs in Initial Diffuse-Type TGCT Patients - - Encore Presentation of Resul...
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that members of the management team will present at the following investor conferences: Jefferies 2019 London Healthca...
Blueprint suffers GIST setbacks NDA changes Blueprint Medicines ( BPMC ) recently announced the FDA will split Avapritinib New Drug Application into separate submissions for PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST, setting the company back a quarter. In order to prioritize ...
Biotech Pulse Biotech finally has a pulse. The improving appetite for risk has resuscitated the moribund biotechs and pharma (biopharma) groups. The Nasdaq Biotech ( IBB ) and the S&P Biotech ( XBI ) indexes have begun their advance from their year-to-date lows recorded earlier in Octo...
Deciphera Pharmaceuticals, Inc. (DCPH) Q3 2019 Earnings Conference Call November 04, 2019, 16:30 ET Company Participants Jennifer Robinson - VP, Investor Relations Steven Hoerter - President, CEO & Director Matthew Sherman - Chief Medical Officer Tucker Kelly - CFO & Tr...
Image source: The Motley Fool. Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) Q3 2019 Earnings Call Nov 4, 2019 , 4:30 p.m. ET Operator Continue reading
Deciphera Pharmaceuticals (NASDAQ: DCPH ): Q3 GAAP EPS of -$1.28 misses by $0.12 . More news on: Deciphera Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
- Ripretinib Granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the Treatment of Patients with Advanced Gastrointestinal Stromal Tumors (GIST) - - Clinical Progress Across Pipeline with Data Presentations for Ripretinib, Rebastinib and DCC-3014 ...
News, Short Squeeze, Breakout and More Instantly...
Deciphera Pharmaceuticals Inc. Company Name:
DCPH Stock Symbol:
NASDAQ Market:
Deciphera Pharmaceuticals Inc. Website:
– MOTION Phase 3 Data Demonstrate Robust Efficacy, Clinically Meaningful Improvements in Quality-of-Life Measures, and Well-Tolerated Safety Profile, Positioning Vimseltinib as Potential New TGCT Treatment – – Company Expects to Submit a New Drug Application (NDA) in ...
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...